WO2007053594A2 - Méthodes d'analyse protéomique à grande fourchette dynamique et compositions pour les mettre en pratique - Google Patents

Méthodes d'analyse protéomique à grande fourchette dynamique et compositions pour les mettre en pratique Download PDF

Info

Publication number
WO2007053594A2
WO2007053594A2 PCT/US2006/042423 US2006042423W WO2007053594A2 WO 2007053594 A2 WO2007053594 A2 WO 2007053594A2 US 2006042423 W US2006042423 W US 2006042423W WO 2007053594 A2 WO2007053594 A2 WO 2007053594A2
Authority
WO
WIPO (PCT)
Prior art keywords
fluorescently labeled
labeled detection
agent
detection agent
analyte
Prior art date
Application number
PCT/US2006/042423
Other languages
English (en)
Other versions
WO2007053594A3 (fr
Inventor
Mark T. Kozlowski
Grigoriy Simeonov Tchaga
Original Assignee
Clontech Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clontech Laboratories, Inc. filed Critical Clontech Laboratories, Inc.
Publication of WO2007053594A2 publication Critical patent/WO2007053594A2/fr
Publication of WO2007053594A3 publication Critical patent/WO2007053594A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Definitions

  • Proteomics involves the qualitative and quantitative measurement of gene products and their activity by detecting and quantitating expression at the protein level, rather than at the messenger RNA level. Proteomics also involves the study of non-genome encoded events, including the post-translational modification of proteins, interactions between proteins, and the location of proteins within a cell. The structure, function, or level of activity of the proteins expressed by the cell are also of interest.
  • Proteomics is of increasing interest for a number of reasons, including the fact that measuring the mRNA abundances of a cell potentially provides only an indirect and incomplete assessment of the protein content of the cell, as the level of active protein that is produced in a cell is often determined by factors other than the amount of mRNA produced, e.g. post-translational modifications, etc.
  • Methods of determining whether a sample includes one or more analytes, such as proteinaceous analytes, of interest are provided. Aspects of the methods include contacting the sample with a solid support that includes an affinity agent for the analyte immobilized on a surface thereof and then detecting the presence of resultant substrate surface bound analyte by assessing signal produced from a large dynamic range signal producing system. Aspects of embodiments of the large dynamic range signal producing system include the presence of a first fluorescently labeled detection agent that specifically binds to the analyte; and a second fluorescently labeled detection agent that specifically binds to the first fluorescently labeled detection agent.
  • the second fluorescently labeled detection agent includes a greater number of fluorescent moieties than the first fluorescently labeled detection agent.
  • kits, systems and other compositions of matter for practicing the subject methods find use in a variety of applications, including but not limited to proteomic applications such as protein expression analysis, e.g., differential protein expression profiling.
  • the subject invention provides highly sensitive methods of determining the presence, often in at least semi-quantitative if not quantitative terms, of one or more, including a plurality of, analytes in a sample.
  • the subject methods are highly sensitive, they are capable of detecting the presence of an analyte in a sample where the analyte is present in a low concentration.
  • the methods are capable of detecting an analyte in a sample where the analyte is present in a concentration as low as about 10 pg/mL or lower, where the concentration of the analyte may be as low as about 10 pg/mL, including as low as about 200 pg/mL or lower.
  • the lower limit of detection of the subject methods i.e., the lowest analyte concentration detectable by the subject methods is, in certain embodiments, at least about 10 pg/mL, such as at least about 100 pg/mL and including at least about 200 pg/mL
  • the methods are methods of detecting an analyte in a sample where the analyte concentration ranges from about 50 pg/ml_ to about 300 ng/mL, such as from about 100 pg/mL to about 100 ng/mL and more including from about 200 pg/mL to about 30 ng/mL.
  • the subject methods are particularly suited for the detection of proteinaceous analytes, i.e., polypeptides, where the term polypeptide is used broadly to describe any molecule having two or more amino acid residues covalently bonded to each other by a peptide bond.
  • embodiments of the methods are suitable for use in detecting analytes that are small polypeptides as well as whole proteins and fragments thereof.
  • the analytes are proteins.
  • aspects of the invention include a large dynamic range of sensitivity, such that the methods can be readily employed to determine a large dynamic range, i.e., wide concentration range, of analyte in a sample, such as from the lower limits reviewed above to large amounts (i.e., concentrations) of analyte, e.g., micrograms/ml, milligrams/ml, etc.
  • This large dynamic range is, in certain embodiments, obtained without any sample dilution, such that large dynamic range can be obtained from a single sample without making one or more sample dilutions and testing each dilution individually.
  • Large dynamic range signal producing systems include first and second detection agents, where each detection agent is labeled with a distinguishable label, e.g., a fluorescent label.
  • a distinguishable label e.g., a fluorescent label.
  • the number of labels in the second detection agent exceeds the number of labels in the first detection agent, e.g., by about 5 % or more, such as by about 10% or more and including by about 25% or more.
  • the subject methods are methods of simultaneously detecting, e.g., quantitatively detecting, the presence of two or more, i.e., a plurality, of analytes in a sample, w, such as at least about 5 or more and including at least about 10 or more, where in representative embodiments at least about 20 different analytes, such as at least about 50 and sometimes at least about 100 or more different analytes are assayed simultaneously, such as 200 or more, 300 or more, 400 or more, etc.
  • Embodiments of the methods may be used with a variety of different types of samples and still provide the above-described sensitivity and large dynamic range.
  • the sample may be a highly complex sample, such as a crude cell extract, or an at least partially purified sample, as well as purified sample. Because of the convenience, in representative embodiments the sample is a crude cell extract, where the only treatment employed may be a dilution step and/or removal of cellar debris step.
  • aspects of the invention such as the types of solid supports, types of samples, large dynamic range signal producing system, etc., are now reviewed separately in greater detail.
  • a solid support i.e., substrate having at least one surface immobilized affinity agent is employed.
  • embodiments of the invention may employ a solid support having a single type of surface immobilized affinity agent immobilized on a surface thereof.
  • the solid support includes a plurality of different affinity agents immobilized on a surface thereof.
  • embodiments of the methods include the use of an array of a plurality of distinct affinity (i.e., binding) agents.
  • the affinity agent i.e., analyte binding agent
  • the affinity agent is a molecule that has a high binding affinity for a target analyte.
  • high binding affinity is meant a binding affinity of at least about 10 "4 M, such as at least about 10 "6 M or higher, e.g., 10 "9 M or higher.
  • the affinity agent may be any of a variety of different types of molecules, so long as it exhibits the requisite binding affinity for the target analyte when immobilized on the surface of a substrate.
  • the affinity agent is a small molecule or large molecule ligand.
  • small molecule ligand is meant a ligand ranging in size from about 50 to about 10,000 daltons, usually from about 50 to about 5,000 daltons and more usually from about 100 to about 1000 daltons.
  • large molecule is meant a ligand ranging in size from about 10,000 daltons or greater in molecular weight.
  • the small molecule may be any molecule, as well as binding portion or fragment thereof, that is capable of binding with the requisite affinity to the target analyte.
  • the small molecule is a small organic molecule that is capable of binding to the target analyte of interest.
  • the small molecule may include one or more functional groups necessary for structural interaction with the target analyte, e.g., groups necessary for hydrophobic, hydrophilic, electrostatic or even covalent interactions.
  • the agent may include functional groups necessary for structural interaction with proteins, such as hydrogen bonding, hydrophobic-hydrophobic interactions, electrostatic interactions, etc., and may include at least an amine, amide, sulfhydryl, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups.
  • Small molecule affinity agents may include cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups.
  • structures found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Such compounds may be screened to identify those of interest, where a variety of different screening protocols are known in the art.
  • the small molecule may be derived from a naturally occurring or synthetic compound that may be obtained from a wide variety of sources, including libraries of synthetic or natural compounds.
  • libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced.
  • natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries.
  • Known small molecules may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.
  • the small molecule may be obtained from a library of naturally occurring or synthetic molecules, including a library of compounds produced through combinatorial means, i.e., a compound diversity combinatorial library.
  • a library of compounds produced through combinatorial means i.e., a compound diversity combinatorial library.
  • the small molecule employed will have demonstrated some desirable affinity for the protein target in a convenient binding affinity assay.
  • Combinatorial libraries as well as methods for the production and screening, are known in the art and described in: 5,741 ,713; 5,734,018; 5,731 ,423; 5,721 ,099; 5,708,153; 5,698,673; 5,688,997; 5,688,696; 5,684,711; 5,641 ,862; 5,639,603; 5,593,853; 5,574,656; 5,571 ,698; 5,565,324; 5,549,974; 5,545,568; 5,541 ,061 ; 5,525,735; 5,463,564; 5,440,016; 5,438,119; 5,223,409, the disclosures of which are herein incorporated by reference.
  • polynucleic acid aptimers are also suitable for use as binding domains.
  • Polynucleic acid aptamers may be RNA oligonucleotides which may act to selectively bind proteins, much in the same manner as a receptor or antibody (Conrad et al., Methods Enzymol. (1996), 267(Combinatorial Chemistry), 336-367).
  • the affinity ligand is a nucleic acid, e.g., an amptamer
  • the target analyte is not a nucleic acid.
  • the affinity ligand is not a nucleic acid.
  • the affinity agent can also be a large molecule, lncertain embodiments, large molecule affinity agents that are employed are antibodies, as well as binding fragments and mimetics thereof.
  • antibodies are the affinity agent, they may be derived from polyclonal compositions, such that a heterogeneous population of antibodies differing by specificity are each tagged with the same tag nucleic acid, or monoclonal compositions, in which a homogeneous population of identical antibodies that have the same specificity for the target protein are each tagged with the same tag nucleic acid.
  • the affinity agent may be either a monoclonal and polyclonal antibody.
  • the affinity agent is an antibody binding fragment or mimetic, where these fragments and mimetics have the requisite binding affinity for the target protein.
  • antibody fragments such as Fv, F(ab) 2 and Fab may be prepared by cleavage of the intact protein, e.g., by protease or chemical cleavage.
  • recombinantly produced antibody fragments such as single chain antibodies or scFvs, where such recombinantly produced antibody fragments retain the binding characteristics of the above antibodies.
  • Such recombinantly produced antibody fragments generally include at least the VH and VL domains of the subject antibodies, so as to retain the binding characteristics of the subject antibodies.
  • antibodies, fragments and mimetics thereof may be obtained from commercial sources and/or prepared using any convenient technology, where methods of producing polyclonal antibodies, monoclonal antibodies, fragments and mimetics thereof, including recombinant derivatives thereof, are known to those of the skill in the art.
  • the solid support is one that displays a plurality of distinct affinity agents immobilized on a surface, e.g., in an addressable manner, such as is found on an array.
  • each of the plurality of different affinity agents immobilized on the solid support surface is one that includes at least an epitope binding domain of an antibody molecule.
  • the solid support employed in the methods are characterized by having a plurality of probe spots, each made up of a distinct binding agent (i.e., a plurality of copies of distinct binding agent molecule) stably associated with the surface of a solid support.
  • Each probe composition of the subject arrays of certain of these embodiments is made up of multiple copies of a binding agent, where each binding agent includes at least an epitope binding domain of antibody.
  • epitope binding domain is meant a region or portion of an antibody molecule that specifically binds to an antigen, more particularly a determinant or epitope of a given antigen.
  • the binding agents are antibodies, as well as specific antigen binding fragments and mimetics thereof.
  • antibodies are the binding agent, they may be derived from polyclonal compositions, such that a heterogeneous population of antibodies differing by specificity are each immobilized on the substrate surface, or monoclonal compositions, in which a homogeneous population of identical antibodies that have the same specificity for the target analyte, e.g., protein, are each immobilized on the substrate surface.
  • the binding agent may be either a monoclonal or a polyclonal antibody in certain embodiments.
  • the binding agent making up the subject probe compositions is an antibody binding fragment or mimetic, where these fragments and mimetics have the requisite binding affinity for the target analyte, e.g., protein.
  • antibody fragments such as Fv, F(ab)2 and Fab may be prepared by cleavage of the intact protein, e.g. by protease or chemical cleavage.
  • recombinantly produced antibody fragments such as single chain antibodies or scFvs, where such recombinantly produced antibody fragments retain the binding characteristics of the above antibodies, i.e., they include the epitope binding domain (which means the whole domain or a least a functional portion thereof) of an antibody specific for the particular analyte.
  • Such recombinantly produced antibody fragments generally include at least the VH and VL domains of the subject antibodies, so as to retain the binding characteristics of the subject antibodies.
  • the above-described antibodies, fragments and mimetics thereof may be obtained from commercial sources and/or prepared using any convenient technology, where methods of producing polyclonal antibodies, monoclonal antibodies, fragments and mimetics thereof, including recombinant derivatives thereof, are known to those of the skill in the art.
  • the binding agents have, in certain embodiments, a strong affinity for their analyte, where this affinity is at least about 10 "6 , such as at least about 10 "8 and includes ranges from about 10 '8 to about 10 "13 , such as from about 10 '9 to about 10 "12 , where the affinity is the affinity as measured following immobilization of the antibody onto the surface using the binding affinity assay described in Pellequer, J. L., Van Regenmortel, M.
  • the probe spots made up of the binding agents as described above and present on the array may be any convenient shape, such as circular, elliptoid, oval or some other analogously curved shape.
  • the total amount or mass of molecules present in each spot will be sufficient to provide for adequate binding and detection of analytes during the assay in which the array is employed.
  • the total mass of binding agents in each spot is at least about 10 pg, such as at least about 100 pg and including at least about 1 ng, where the total mass may be as high as 20 ng or higher, and in certain embodiments does not exceed about 10 ng and in certain embodiments does not exceed about 5 ng.
  • the diameter of the spot may range from about 10 to about 5,000 ⁇ m, such as from about 20 to about 1 ,000 ⁇ m and including from about 50 to about 500 ⁇ m.
  • the surface area of each spot may be at least about 100 ⁇ m 2 , such as at least about 200 ⁇ m 2 and including at least about 400 ⁇ m 2 , and may be as great as about 25 mm 2 or greater, and in certain embodiments does not exceed about 5 mm 2 , and in certain embodiments, does not exceed about 1 mm 2 .
  • the density of binding agents "probe" spots on the array, as well as the overall density of probe and non-probe spots may vary greatly.
  • the term spot refers to any spot on the array surface that is made up of binding agents, whether control or probe binding agents, and as such includes both probe spots and non-probe spots.
  • the density of the probe spots on the solid surface is, in certain embodiments, at least about 5/cm 2 such as at least about 10/cm 2 and may be as high as about 100/cm 2 , about 200/cm 2 , about 300/cm 2 , about 500 /cm 2 , about 1000/cm 2 , about 5000/cm 2 or higher, and in certain embodiments does not exceed about 1000/cm 2 , and in these embodiments may not exceed about 500/cm 2 or about 400/cm 2 , and in certain embodiments does not exceed about 300/cm 2 .
  • the spots may be arranged in a spatially defined and physically addressable manner, in any convenient pattern across or over the surface of the array, such as in rows and columns so as to form a grid, in a circular pattern, and the like, where the pattern of spots may be present in the form of a grid across the surface of the solid support.
  • the spots of the pattern are stably associated with, i.e., immobilized on, the surface of a solid support, where the support may be a flexible or rigid support.
  • stably associated it is meant that the binding agents of the spots maintain their position relative to the solid support under incubation and washing conditions, as described below.
  • the individual binding agent members that make up the spots can be non-covalently or covalently stably associated with the support surface based on technologies well known to those of skill in the art.
  • non-covalent association include non-specific adsorption, binding based on electrostatic (e.g. ion, ion pair interactions), hydrophobic interactions, hydrogen bonding interactions, specific binding through a specific binding pair member covalently attached to the support surface, and the like.
  • covalent binding include covalent bonds formed between the spot binding agents and a functional group present on the surface of the rigid support, where the functional group may be naturally occurring or present as a member of an introduced linking group.
  • the binding agents making up the spots on the array surface are covalently bound to the support surface, e.g., through covalent linkages formed between moieties present on the binding agents, e.g., amines, and the substrate surface, etc, as may be present on a glass substrate, e.g., aminated glass. See e.g., the specific covalent attachment protocol exemplified below.
  • the array is present on either a flexible or rigid substrate.
  • flexible is meant that the support is capable of being bent, folded or similarly manipulated without breakage.
  • solid materials which are flexible solid supports with respect to the present invention include membranes, flexible plastic films, and the like.
  • rigid is meant that the support is solid and does not readily bend, i.e. the support is not flexible.
  • the rigid substrates of the subject arrays are sufficient to provide physical support and structure to the polymeric targets present thereon under the assay conditions in which the array is employed, particularly under high throughput handling conditions.
  • the rigid supports of the subject invention are bent, they are prone to breakage.
  • the solid supports upon which the subject binding agent(s), e.g., in the form of patterns of spots, are presented in the subject substrates (e.g., arrays) may take a variety of configurations ranging from simple to complex, depending on the intended use of the array.
  • the solid support could have an overall slide or plate configuration, such as a rectangular or disc configuration.
  • the solid support has a rectangular cross-sectional shape, having a length of from about 10 mm to 200 mm, such as from about 40 to 150 mm and including from about 75 to 125 mm and a width of from about 10 mm to 200 mm, such as from about 20 mm to 120 mm and including from about 25 to 80 mm, and a thickness of from about 0.01 mm to 5.0 mm, such as from about 0.01 mm to 2 mm and including from about 0.01 to 1 mm.
  • the support may have a micro-titre plate format, having dimensions of approximately 125x85 mm.
  • the support may be a standard microscope slide with dimensions of from about 25 x 75 mm.
  • the solid supports may be fabricated from a variety of materials.
  • the materials from which the solid support is fabricated exhibit a low level of nonspecific binding during binding events in certain embodiments.
  • a material that is transparent to visible and/or UV light is employed.
  • materials of interest include, but are not limited to: nylon, both modified and unmodified, nitrocellulose, polypropylene, and the like.
  • specific materials of interest include, but are not limited to: glass; plastics, e.g. polytetrafluoroethylene, polypropylene, polystyrene, polycarbonate, and blends thereof, and the like; metals, e.g. gold, platinum, and the like; etc.
  • composite materials such as glass or plastic coated with a membrane, e.g., nylon or nitrocellulose, etc.
  • the solid supports of the arrays of these particular embodiments include at least one surface on which the pattern of spots is present, where the surface may be smooth or substantially planar, or have irregularities, such as depressions or elevations.
  • the surface on which the pattern of spots is present may be modified with one or more different layers of compounds that serve to modify the properties of the surface in a desirable manner.
  • Such modification layers when present, will generally range in thickness from a monomolecular thickness to about 1 mm, usually from a monomolecular thickness to about 0.1 mm and more usually from a monomolecular thickness to about 0.001 mm.
  • Modification layers of interest include: inorganic and organic layers such as metals, metal oxides, polymers, small organic molecules and the like.
  • Polymeric layers of interest include layers of: peptides, proteins, polynucleic acids or mimetics thereof, e.g. peptide nucleic acids and the like; polysaccharides, phospholipids, polyurethanes, polyesters, polycarbonates, polyureas, polyamides, polyethyleneamines, polyarylene sulfides, polysiloxanes, polyimides, polyacetates, polyacrylamides, and the like, where the polymers may be hetero- or homopolymeric, and may or may not have separate functional moieties attached thereto, e.g. conjugated.
  • an antibody universal binding layer is present on the substrate surface, e.g., covalently bound to the substrate surface, which layer acts as a linking group or tethering element between the antibody binding agent in the substrate surface and serves to tether the antibody binding agent to the substrate surface.
  • the basic principle is to utilize proteins and ligands with affinity towards antibodies (including but not limited to Protein A, Protein G, Protein L, Protein LA) which are covalently immobilized to a glass, plastic or any other type of surfaces. After the immobilization of the universal binding layer, the antibody binding agents are deposited on the same locations and reversibly immobilized.
  • the universal binding layer of affinity ligands thus forms a layer which protects the consequently bound antibodies from detrimental surface effects.
  • An additional benefit is the directed mode of immobilization as compared to that of direct covalent attachment of the antibodies to activated surfaces. This results in 100 % availability of the antigen binding sites on the antibodies for consequent detection of antigens. It also provides universal conditions for binding, since the formation of ligand/antibody complex is obtained under mild physiological conditions where as covalent immobilization of proteins is often performed under conditions that might be detrimental to their biological activity.
  • the total number of spots on the solid support surface will vary depending on the number of different probe spots (binding agent probe compositions) one wishes to display on the surface, as well as the number of non probe spots, e.g., control spots, orientation spots, calibrating spots and the like, as may be desired depending on the particular application in which the subject arrays are to be employed.
  • the pattern present on the surface of the support will comprise at least about 10 distinct spots, such as at least about 20 spots, and including at least about 50 distinct spots, where the number of distinct spots may be as high as 10,000 or higher, but in certain embodiments does not exceed about 5,000 distinct spots, and in certain embodiments does not exceed about 3,000 distinct spots, e.g., does not exceed about 2,000 distinct spots.
  • each distinct probe spot or probe composition is presented in duplicate, i.e., so that there are two duplicate probe spots displayed on the array for a given target.
  • the number of probe spots present in the array makes up a substantial proportion of the total number of spots on the array in certain embodiments, where in representative embodiments the number of probe spots is at least about 50 number %, such as at least about 80 number % and including at least about 90 number % of the total number of spots on the array.
  • the total number of spots on the array ranges from about 10 to about 20,000, such as from about 20 to about 10,000 and including from about 100 to 5,000.
  • a single pattern of probe spots may be present on the array or the array may include a plurality of different spot patterns, each pattern being as defined above.
  • the patterns may be identical to each other, such that the array comprises two or more identical spot patterns on its surface, or the spot patterns may be different, e.g., in arrays that have two or more different sets of probes present on their surface, e.g., an array that has a pattern of spots corresponding to first population of target analytes and a second pattern of spots corresponding to a second population of analytes.
  • the number of different spot patterns is at least 2, usually at least 6, more usually at least 24 or 96, where the number of different patterns will generally not exceed about 384.
  • the array may include a plurality of reaction chambers, wherein each chamber has a bottom surface having associated therewith an pattern of spots and at least one wall, usually a plurality of walls surrounding the bottom surface. See e.g. U.S. Patent No. 5,545,531 , the disclosure of which is herein incorporated by reference.
  • any given pattern of spots on the array there may be a single spot that corresponds to (i.e., specifically binds to) a given analyte target or a number of different spots that correspond to the same analyte, where when a plurality of different spots are present that correspond to the same analyte, the probe compositions of each spot that corresponds to the same analyte may be identical or different.
  • a plurality of different analytes are represented in the pattern of spots, where each analyte may correspond to a single spot or a plurality of spots, where the probe compositions among the plurality of spots corresponding to the same analyte may be the same or different.
  • any given analyte is represented by only a single type of probe spot, which may be present only once or multiple times on the array surface, e.g. in duplicate, triplicate etc.
  • the number of distinct or different probe spots present on the array, and therefore the number of different analytes represented on the array is, in certain embodiments, at least about 2, such as at least about 10 and including at least about 20, where in representative embodiments the number of different analytes represented on the array is at least about 50 and may be at least about 100.
  • the number of different analytes represented on the array may be as high as 5,000 or higher, but in representative embodiments does not exceed about 3,000, such as not more than about 2,500.
  • An analyte is considered to be represented on an array if it is able to specifically bind to one or probe compositions on the array.
  • the arrays employed in aspects of the methods may be fabricated using any convenient protocol, where the protocol may vary depending on the nature of the substrate, the nature of any intervening surface layer, e.g., whether or not a universal binding layer is present, and the nature of the binding agents.
  • the solid support is a glass substrate or analogous material
  • the surface of the support is first activated to provide for functional groups suitable for use in the covalent bonding, either directly or through a linking group, of the binding agent.
  • glass surfaces may be aminated so as to display amine functional groups via silanization, according to well known surface chemistry protocols.
  • the binding agent is then immobilized on the functionalized surface, e.g., through direct or indirect covalent bonding, e.g., by non-covalent binding to a covalently bound universal binding layer of molecules, as described above.
  • a surface activation agent e.g., that provides a linking group capable of forming a covalent linkage between aminated moieties, such as PIDTC and DVS, as exemplified in the experimental section below.
  • a binding agent composition is immobilized on the substrate surface to produce a spot of the array.
  • the binding agent composition is typically an aqueous composition.
  • the concentration ranges of the deposited binding agent composition is at least about 0.1 mg/mL, such as at least about 0.2 mg/mL, where the concentration may be as great as 1 mg/mL or greater.
  • the purity of the binding agent composition is, in representative embodiments, at least about 90%, such as at least about 95% and including at least about 97% % pure.
  • the binding agent composition is deposited on the array surface using any convenient protocol. In certain embodiments, the binding agent composition is applied using a pin or analogous fluid deposition device.
  • a functional probe spot i.e., a probe spot that specifically binds to its target analyte.
  • the surface is then contacted with a blocking agent in order to block non-specific binding sites on the array surface.
  • a blocking agent Any convenient blocking agent may be employed, where representative blocking agents include, but are not limited to, nonfat milk, BSA, gelatin, preimmune serum and the like, where standard blocking protocols may be employed.
  • the array may be stored for a period of time prior to use, as desired.
  • the array may be stored in any convenient format, including both dry and wet formats, so long as the activity of the array, i.e., the binding ability of the probe spots on the array for their specific analytes, is not adversely affected.
  • not adversely affected is meant that the sensitivity of the array does not change with respect to a given a ⁇ alyte as compared to the array immediately following blocking by a value that exceeds about 10 fold, and usually does not change by a value that exceeds about 5 fold.
  • the period of time for which the array is stored prior to use in the subject methods is at least about 2 days, usually at least about 6 months and more usually at least about 9 months and may be as long as about 1 year or longer, where the array is typically not stored for a period that exceeds about 6 months prior to use.
  • the sample that is contacted with the solid support surface may vary greatly, depending upon the nature of the assay to be performed.
  • the sample is an aqueous fluid sample.
  • the amount of fluid sample also varies with respect to the nature of the device, the nature of the sample, etc.
  • the amount of sample that is contacted with the solid support surface ranges from about 100 ⁇ l to about 10 ml, such as from about 1 mL to about 8 ml and including from about 4 to about 6 ml.
  • the fluid sample is a naturally occurring sample, where the sample may or may not be modified prior to contact with the solid support.
  • the fluid sample is obtained from a physiological source, where the physiological source may be eukaryotic, with physiological sources of interest including sources derived from single celled organisms such as yeast and multicellular organisms, including plants and animals, such as mammals, where the physiological sources from multicellular organisms may be derived from particular organs or tissues of the multicellular organism, or from isolated cells or cellular compartments, e.g., nucleus, cytoplasm, etc., derived therefrom.
  • the initial physiological source e.g., tissue, collection of cells, etc.
  • the initial physiological source e.g., tissue, collection of cells, etc.
  • processing steps might include tissue homogenization, protein extraction and the like, where such processing steps are known to the those of skill in the art.
  • tissue homogenization e.g., tissue homogenization
  • protein extraction e.g., protein extraction
  • processing steps might include tissue homogenization, protein extraction and the like, where such processing steps are known to the those of skill in the art.
  • cellular extracts e.g., cell extracts, etc.
  • the initial fluid sample derived from a particular source may be subjected to a fractionation protocol that reduces the complexity of the protein composition of the sample.
  • reduce the complexity is meant that the total mass of all of the proteins in the sample is reduced by at least about 10 fold, such as by at least about 100 fold and including by at least about 1000 fold.
  • the fractionation protocol employed is one that reduces the amount of highly abundant proteins in the sample.
  • a pool of covalently attached antibodies e.g., one or more columns of antibodies, is employed for enrichment of antigen analytes of interest from an initial sample, e.g., whole cell extracts.
  • the non adsorbed material is washed away with washing buffer and the specifically retarded antigens are eluted and collected for further labeling and incubation with the array containing binding agent spots for the antigen/analytes of interest, e.g., the same antibodies that were used for initial enrichment.
  • the initial sample is fractionated so as to reduce the complexity and enrich the sample for the analytes of interest.
  • the analyte containing fluid sample is contacted with the solid support surface and contact is maintained under sufficient conditions and for a period of time sufficient for binding of analyte to specific binding agent on the solid support surface to occur.
  • the array and analyte containing sample are incubated together for at least about 10 min., such as at least about 20 min., and including at least about 30 min., where the incubation time may be as long as about 480 min. or longer, but in certain embodiments does not exceed about 60 min.
  • the solid support surface and sample are maintained at a temperature that may range in certain embodiments from about 20 0 C to about 28 0 C 1 such as from about 22 0 C to about 26 0 C.
  • the array and sample are subjected to mixing or agitation during the incubation step.
  • a feature of the incubation step is that present in the analyte containing fluid medium contacted with the substrate surface during incubation is a metal ion chelating polysaccharide, i.e., a polysaccharide that chelates metal ions, wherein the polysaccharide may be a charged molecule.
  • the polysaccharide may be a naturally occurring or synthetic molecule, and may be a homopolymeric or heteropolymeric compound.
  • the molecular weight of the polysaccharide may vary greatly, but in certain embodiments ranges from about 10,000 to 2,500,000 daltons, such as from about 10,000 to 500,000 daltons, where in certain embodiments a population of polysaccharide molecules of different weights are present in the analyte containing fluid medium during incubation.
  • the total amount of metal chelating polysaccharide present in the analyte containing fluid medium may range from about 0.01% to about 2%, such as from about 0.2% to about 1%.
  • the metal chelating polysaccharide is a heteropolymeric compound that includes polygalactouronate sequences.
  • pectins like fruit pectins, e.g., citrus pectin (e.g., lemon, orange), apple pectin, tomato pectin, and the like.
  • the pH of the liquid medium may be maintained at a value ranging from about 6.5 to about 8.5, such as from about 7.0 to about 8.0.
  • buffers e.g., Tris, sodium citrate and the like; salts, e.g., NaCI, sodium sulfate, and the like; surfactants/surfactants, e.g., Pluronics, Tweens, glycerol, ethylene glycol, etc.
  • the initial sample is first pre-incubated with an incubation buffer that includes the metal ion chelating polysaccharide to produce a preincubated analyte containing sample, which preincubated sample is then contacted with the substrate for the incubation period.
  • the incubation buffer typically includes a number of additional components, including buffering agents, salts, surfactants, etc.
  • the substrate and sample may be contacted and incubated in the presence of a known amount of a competitor that competes with said analyte for binding to said affinity agent immobilized on said substrate surface.
  • a known amount of an analyte competitor e.g., analyte or binding fragment thereof, may be included in the sample.
  • washing Following incubation, non-support bound components of the analyte containing medium contacted with the support surface during incubation are separated or removed from the surface in certain embodiments.
  • This separation step may be accomplished using one or more washing steps, as desired, in which the substrate surface is contacted and separated from, including flushed with, one or more different fluid compositions.
  • the support surface is subjected to a sequential washing protocol, in which the support surface is washed with a plurality of distinct washing solutions.
  • the number of different washings employed in these embodiments varies, but ranges in certain embodiments from about 3 to 10, such as from about 5 to 9 and including from about 6 to 8, where in certain embodiments, 7 distinct washings are employed.
  • the series of different washing mediums employed provides a modulation or change in the nature of the washing medium and components therein, e.g., in order to subject the array surface to a sequential or step-wise change or modulation of conditions, e.g., amount/type of detergent, salt concentration, buffering agent, additives, etc.
  • the different washing conditions to which the support is subjected during the sequential wash protocol are ones that provide for a decrease in background and cross-reactivity during detection, and therefore an increase in signal to noise ratio and/or selectivity, so as to provide the sensitive results discussed above.
  • the washing conditions are ones that provide for an increase in signal to noise ratio and/or selectivity of at least about 2- fold, such as at least about 5-fold and including at least about 10 fold and compared to a control assay in which only a single wash step with a wash fluid that is the same as the incubation fluid is performed.
  • the sequential wash protocol is characterized by initially employing a high salt wash, e.g., to remove electrostatically bound molecules, followed by sequential use of wash fluids of decreasing detergent composition, and/or a change of buffers, e.g., from Tris to sodium citrate.
  • a fluorescence quenching decreasing agent e.g., polyethyleneimine and other agents that provide for a decrease in fluorescence quenching and therefore an increase in signal to noise ratio.
  • aspects of the subject methods include the use of a large dynamic range signal producing system.
  • a feature of the large dynamic range signal producing systems employed in embodiments of the invention is the presence of: (i) a first fluorescently labeled detection agent that specifically binds to a surface immobilized member, e.g., target analyte; and (ii) a second fluorescently labeled detection agent that specifically binds to the first fluorescently labeled detection agent.
  • the first and second detection agents may specifically bind directly or indirectly to their targets (e.g., target analyte or first detection agent, respectively), such that they may bind directly to their targets or via one or more binding mediation members, e.g., non-covalent specific binding pair members, such as ligands, e.g. biotin, fluorescein, digoxigenin, other haptens, polyvalent cations, chelator groups and the like.
  • the first detection agent binds directly to the target analyte, e.g., that is bound to the surface immobilized binding agent.
  • the second fluorescently labeled detection agent directly binds to the first fluorescently labeled detection agent.
  • the second fluorescently labeled detection agent indirectly binds to the first fluorescently labeled detection agent.
  • the first fluorescently labeled detection agent is capable of indirectly binding to a plurality of second fluorescently labeled detection agents. Aspects of these embodiments include the use of a detection agent that can be bound by a signal amplification agent, e.g., a biotinylated antibody as reviewed below, such that a plurality of second detection agents can be indirectly bound to the first detection agent.
  • the first fluorescently labeled detection agent includes: an affinity agent, such as antibody or binding fragment thereof, that specifically binds to the target analyte; and a first fluorescent label.
  • the first detection agent is labeled with a first fluorescent label.
  • labeled is meant that the detection agent is joined to, either covalently bonded to or stably but non- covalently bound to, a first fluorescent label.
  • fluorescent moieties or labels of interest include, but are not limited to: coumarin and its derivatives, e.g. 7- amino-4-methylcoumarin, aminocoumarin, bodipy dyes, such as Bodipy FL, cascade blue, fluorescein and its derivatives, e.g.
  • fluorescein isothiocyanate Oregon green
  • rhodamine dyes e.g. texas red, tetramethylrhodamine, eosins and erythrosins
  • cyanine dyes e.g. Cy3 and Cy5
  • macrocyclic chelates of lanthanide ions e.g. quantum dyeTM
  • fluorescent energy transfer dyes such as thiazole orange-ethidium heterodimer, TOTAB 1 etc.
  • the first fluorescent label is a proteinaceous label, such as a phycobiliprotein or complex thereof, e.g., a phycobilisome.
  • a proteinaceous label such as a phycobiliprotein or complex thereof, e.g., a phycobilisome.
  • Various phycobiliproteins can be used as the first fluorescent moiety. These phycobiliproteins may be allophycocyanin, allophycocyanin B, C-phycocyanin, R- phycocyanin, C-phycoerythrin, B-phycoerythrin, B-phycoerythrin I and II, and the like.
  • the phycobiliproteins may be obtained from various species of cyanobacteria (blue-green algae), red algae and cryptomonads.
  • the second fluorescently labeled detection agent of the large dynamic range signal producing system includes: an affinity agent that specifically binds to the first fluorescently labeled detection agent, either directly or indirectly; and a second fluorescent label.
  • the second detection agent is made up of a single molecule that includes the above recited components, while in other embodiments the second detection agent is made up of two or more distinct molecules, wherein the different elements are present on different molecules.
  • aspects of this second embodiment include embodiments where the affinity agent is present on a first molecule that specifically binds to the first detection agent, and then the fluorescent label is present on a second molecule that specifically binds to the affinity agent comprising molecule, e.g., via a high affinity specific binding member pair interaction, such as a biotin/avidin or streptavidin interaction.
  • the second detection agent includes a first molecule that is a biotinylated affinity agent for the first detection agent, and a second molecule that includes avidin or streptavidin conjugated to a second fluorescent moeity.
  • the second fluorescent moiety may include a single fluorescent entity or a plurality of distinct entities that are associated (either covalently or non-covalently) with each other to produce a fluorescent complex, e.g., in the form of a naturally occurring or synthetic phycobilisome.
  • the fluorescent moiety of the second detection agent may any of a variety of different fluorescent entities.
  • the second fluorescent moiety is made up of one or more fluorescent proteinaceous molecules, such as phycobiliproteins.
  • the second fluorescent detection agent is a conjugate of avidin or streptavidin and a stabilized, e.g., crosslinked, complex of two or more, e.g., three or more, different or distinct phycobiliproteins, e.g., APCT, B-PE and R-PC, such as is marketed by Martek Biosciences under the tradename PBXL-3. See e.g., Technical Bulletin 2, Martek Biosciences, June 2002.
  • the second fluorescent moiety is made up of non- covalently associated or bonded different phycobiliproteins, e.g., such as APC in combination with one or both of B-PE and R-PC.
  • ratio of different phycobiliproteins may vary, but in certain embodiments may be 1 APC and/or R-PC for every 5 to 10 B-PE.
  • the first and second fluorescent labels when immobilized on the solid support surface, e.g., via specific binding to the support immobilized affinity agent capture analyte (or mimetic thereof or agent itself, depending on the particular assay format, e.g., direct or competitive), are present in a fluorescent energy transfer (FET), such as a fluorescent resonance energy transfer (FRET) relationship.
  • FET fluorescent energy transfer
  • FRET fluorescent resonance energy transfer
  • the first and second fluorescent moieties are chosen to provide this relationship, e.g., by having the first fluorescent moiety of the first detection agent serve as a donor and the second fluorescent moiety of the second detection agent serve as an acceptor.
  • Two fluorescent labels are viewed as being a FRET pair for purposes of the present invention if, when positioned sufficiently close to each other (typically less than about 100A, and usually less than about 80A), they participate in fluorescence resonance energy transfer, such that excitation of one of the labels gives rise to emission from the other of the two labels.
  • FRET pairs of fluorescent labels are known to those of skill in the art and may be employed.
  • the energy donors of the pairs will generally be compounds which absorb in the range of about 300 to about 800 nm, such as in the range of about 450 to about 700 nm, and are capable of transferring energy to an acceptor fluorophore, which absorbs light of a wavelength 15 nm, more usually 20 nm or higher, than the absorption wavelength of the donor.
  • the acceptor will emit in the range of about 400 to about 900 nm in certain embodiments.
  • the FRET relationship that is present is not complete, but instead only partial, such that not all of the energy emitted from the donor is taken up by the acceptor.
  • embodiments are characterized in that less than 90% of the energy is transmitted, such as less than 80%, including less than 70% or less, so that an emission signal is still obtainable from the first fluorescent moiety.
  • the analytes of interest present in the sample are contacted with at least some of, if not all of, the members of the large dynamic range signal producing system prior to contact with the support surface. In certain embodiments, the analytes in the sample are not contacted with the signal producing system prior to incubation. Any convenient protocol is acceptable so long as the signal producing system is contacted with the sample contacted support at some point prior to detection, described below. As such, the surface bound analytes may be labeled following incubation and an initial wash step.
  • the support surface is read or scanned for the presence of binding complexes, e.g., between analytes in the assayed sample and binding agents on the substrate surface.
  • binding complexes e.g., between analytes in the assayed sample and binding agents on the substrate surface.
  • analyte/binding agent complexes on the surface of the array are detected in representative embodiments.
  • any convenient protocol may be employed for detecting the binding agents on the support surface.
  • the detection method may be qualitative or quantitative depending on the particular application in which the subject method is being performed, where the particular detection protocol employed may or may not use a detectable label. Representative detection protocols that may be employed include those described in WO 00/04389 and WO 00/04382; the disclosures of the priority applications of which are herein incorporated by reference.
  • a fluorescence scanner device i.e., fluorimeter
  • the methods include assessing or evaluating signal at two or more different wavelengths, e.g., a first wavelength corresponding to an emission maximum of the first fluorescent moiety and a second wavelength corresponding to an emission maximum of the second fluorescent moiety.
  • the signal that is assessed is one that is excited by a narrow wavelength band of excitation light.
  • the presence of any surface bound binding complexes is then related to the presence of the one or more analytes in the sample.
  • the signal intensity value obtained from the signal producing system is quantitatively related to the presence of the corresponding analyte in the sample, so as to provide a quantitative determination of the analyte amount in the sample.
  • this relating step merely comprises determining the location on the surface on which a binding complex is present, comparing that location to a reference that provides information regarding the correlation of each location to a particular analyte and thereby deriving the identity of the analyte in the sample.
  • the location of the surface bound binding complexes is used to determine the identity of the one or more analytes of interest in the sample.
  • the following representative protein assay is summarized. Where one is interested in assaying a sample for the presence of 100 different proteins, an array displaying a collection of 100 different antibody binding agents is prepared, where each different antibody binding agents in the collection specifically binds to a different protein member of the 100 different proteins being assayed.
  • the array is then contacted with the sample being assayed under conditions sufficient for binding complexes to be produced between the probe binding agent spots and their corresponding target proteins in the sample. Any resultant binding complexes on the surface of the array are then detected and the location of the detected binding complexes is used to determine which of the 100 proteins of interest is present in the sample.
  • two or more physiological sources e.g., cell extracts
  • analyte containing sample may be separately contacted to identical arrays or together to the same array under binding conditions, depending on whether a means for distinguishing the patterns generated by the different populations of analytes is employed, e.g. distinguishable labels.
  • the results are internally validating, e.g., where overlapping signals are obtained from the disparate components of the large dynamic signal producing system.
  • kits for use in practicing the subject methods typically include a solid support having a binding agent immobilized on a surface thereof, such as an array of binding agents, as described above, e.g., an array of binding agents where each agent includes an epitope binding domain of an antibody.
  • the kits of representative embodiments include a large dynamic range signal producing system of first and second detection agents, as described above.
  • the subject kits may further include an incubation buffer, as described above, or at least components for making such a buffer, i.e., an incubation buffer that includes a metal ion chelating polysaccharide.
  • the subject kits may also include an extraction/labeling buffer as described above, as well as one or more wash buffers.
  • the subject kits may include a fractionation means, e.g., where fractionated steps are employed, such as the binding agent/antibody columns described above.
  • the kits may include one or more positive or negative controls, e.g., pre-labeled antigen known to have a corresponding control spot on the array, etc.
  • the various components of the kit may be present in separate containers or certain compatible components may be precombined into a single container, as desired.
  • the subject kits mayfurther include instructions for practicing the subject methods. These instructions may be present in the subject kits in a variety of forms, one or more of which may be present in the kit.
  • One form in which these instructions may be present is as printed information on a suitable medium or substrate, e.g., a piece or pieces of paper on which the information is printed, in the packaging of the kit, in a package insert, etc.
  • Yet another means would be a computer readable medium, e.g., diskette, CD, etc., on which the information has been recorded.
  • Yet another means that may be present is a website address which may be used via the internet to access the information at a removed site. Any convenient means may be present in the kits.
  • the subject systems include at least the solid supports and first and second detection agents as described above, and a detector device for detecting surface bound complexes following incubation.
  • the subject systems may also include additional components necessary for practicing a given embodiment of the subject methods, e.g., incubation buffer, extraction/labeling buffer, washing fluid, labeling reagents, etc., as described above.
  • the subject methods find use in a variety of different applications, where certain applications of interest include analyte detection, drug development, toxicity testing, clinical diagnostics, differential protein expression analysis, etc.
  • proteomics in which the subject methods are used to characterize the proteome or some fraction of the proteome of a physiological sample, e.g. a cell, population of cells, population of proteins secreted by a cell or population of cells, etc.
  • proteome is meant the total collection or population of intracellular proteins of a cell or population of cells and the proteins secreted by the cell or population of cells.
  • the subject methods are employed to measure the presence, and usually quantity, of the proteins which have been expressed in the cell of interest, i.e., are present in the assayed physiological sample derived from the cell of interest.
  • the subject methods are employed to characterize and then compare the proteomes of two or more distinct cell types, e.g., a diseased and normal cell.
  • Proteomics applications in which the subject invention finds use are further described in WO 00/04382, WO 00/04389 and WO 00/04390, and the priority U.S. Patent applications on which these international applications are based, the disclosures of which priority applications are herein incorporated by reference.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)

Abstract

L’invention concerne des méthodes pour déterminer si un échantillon comporte une ou plusieurs substances d'intérêt. Elle concerne aussi des compositions, par exemple, des nécessaires, des systèmes et d’autres compositions de matière, pour mettre en pratique lesdites méthodes. Lesdites méthodes et compositions sont utilisées dans diverses applications.
PCT/US2006/042423 2005-10-31 2006-10-31 Méthodes d'analyse protéomique à grande fourchette dynamique et compositions pour les mettre en pratique WO2007053594A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73226205P 2005-10-31 2005-10-31
US60/732,262 2005-10-31

Publications (2)

Publication Number Publication Date
WO2007053594A2 true WO2007053594A2 (fr) 2007-05-10
WO2007053594A3 WO2007053594A3 (fr) 2007-10-04

Family

ID=38006454

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/042423 WO2007053594A2 (fr) 2005-10-31 2006-10-31 Méthodes d'analyse protéomique à grande fourchette dynamique et compositions pour les mettre en pratique

Country Status (1)

Country Link
WO (1) WO2007053594A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8507287B2 (en) 2008-09-26 2013-08-13 Wisconsin Alumni Research Foundation Mesoporous metal oxide materials for phosphoproteomics
US10669569B2 (en) 2010-10-15 2020-06-02 Navinci Diagnostics Ab Dynamic range methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994143A (en) * 1996-02-01 1999-11-30 Abbott Laboratories Polymeric fluorophores enhanced by moieties providing a hydrophobic and conformationally restrictive microenvironment
US6150097A (en) * 1996-04-12 2000-11-21 The Public Health Research Institute Of The City Of New York, Inc. Nucleic acid detection probes having non-FRET fluorescence quenching and kits and assays including such probes
US20010031468A1 (en) * 2000-02-08 2001-10-18 Alex Chenchik Analyte assays employing universal arrays
US20040077026A1 (en) * 1997-05-14 2004-04-22 Biosite, Inc. Rapid evaluation of the ratio of biological molecules
US20050042696A1 (en) * 2001-05-03 2005-02-24 Victor Kovalenko Systems and methods for detection of analytes in biological fluids

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994143A (en) * 1996-02-01 1999-11-30 Abbott Laboratories Polymeric fluorophores enhanced by moieties providing a hydrophobic and conformationally restrictive microenvironment
US6150097A (en) * 1996-04-12 2000-11-21 The Public Health Research Institute Of The City Of New York, Inc. Nucleic acid detection probes having non-FRET fluorescence quenching and kits and assays including such probes
US20040077026A1 (en) * 1997-05-14 2004-04-22 Biosite, Inc. Rapid evaluation of the ratio of biological molecules
US20010031468A1 (en) * 2000-02-08 2001-10-18 Alex Chenchik Analyte assays employing universal arrays
US20050042696A1 (en) * 2001-05-03 2005-02-24 Victor Kovalenko Systems and methods for detection of analytes in biological fluids

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8507287B2 (en) 2008-09-26 2013-08-13 Wisconsin Alumni Research Foundation Mesoporous metal oxide materials for phosphoproteomics
US10669569B2 (en) 2010-10-15 2020-06-02 Navinci Diagnostics Ab Dynamic range methods

Also Published As

Publication number Publication date
WO2007053594A3 (fr) 2007-10-04

Similar Documents

Publication Publication Date Title
WO2002025288A2 (fr) Procedes d'analyse proteomique a haute sensibilite, trousses et systemes utiles pour mettre en oeuvre ces derniers
US20090023144A1 (en) Method and its kit for quantitatively detecting specific analyte with single capturing agent
US10670612B2 (en) Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards
JP5166240B2 (ja) 種々の系列の抗生物質の検出および特定を同時に行なうインビトロ方法およびこの方法による分析キット
US7285426B2 (en) Bulking materials containing starch reagent for use in test devices
Lan et al. Multi-residue detection of pesticides using a sensitive immunochip assay based on nanogold enhancement
US20150094237A1 (en) Quantitative analysis of carbohydrate-protein interactions using glycan microarrays: determination of surface and solution dissociation constants
US8029985B2 (en) Amplified bioassay
Maragos Emerging technologies for mycotoxin detection
US6861251B2 (en) Translucent solid matrix assay device for microarray analysis
US20090227043A1 (en) Fluorescence Resonance Energy Transfer Assay Based on Modified Solid Surface
NZ540219A (en) Fret probes and methods for detecting interacting molecules
US20200333337A1 (en) Method for re-using test probe and reagents in an immunoassay
Zuo et al. Determination of β-adrenergic agonists by hapten microarray
US20040157281A1 (en) Method and apparatus for detecting an analyte
Zhao et al. Competitive immunoassay for microliter protein samples with magnetic beads and near-infrared fluorescence detection
Rissin et al. Duplexed sandwich immunoassays on a fiber-optic microarray
WO2019081361A1 (fr) Dosage immunologique à écoulement latéral universel
WO2007053594A2 (fr) Méthodes d'analyse protéomique à grande fourchette dynamique et compositions pour les mettre en pratique
AU1364300A (en) Quantitative determination of analytes in a heterogeneous system
CA2426446C (fr) Detection d'especes de liaison a structures colloidales et non colloidales
Goryacheva Formats of Rapid Immunotests—Current-Day Formats, Perspectives, Pros and Cons
Yu et al. An impedance biosensor array for label-free detection of multiple antigen-antibody reactions
WO2005036171A1 (fr) Procede et systeme de detection d'un analyte cible
US20050064446A1 (en) Detection of binding species with colloidal and non-colloidal structures

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06827137

Country of ref document: EP

Kind code of ref document: A2